Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 45Lymphoma, Mantle-Cell 22Waldenstrom Macroglobulinemia 12Lymphoma, Non-Hodgkin 10Lymphoma, Large B-Cell, Diffuse 10Lymphoma, Follicular 10Lymphoma, B-Cell 10Leukemia 10Recurrence 7Lymphoma, B-Cell, Marginal Zone 6Lymphoma 6Neoplasms 4Hodgkin Disease 4Leukemia, Prolymphocytic 3Leukemia, Lymphoid 3Leukemia, B-Cell 3Chromosome 17 deletion 3Burkitt Lymphoma 3Bronchiolitis Obliterans Syndrome 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Leukemia, Hairy Cell 2Hematologic Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1Prostatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Plasma Cell 1Neoplasm, Residual 1

Interventions

Temozolomide 6Capecitabine 4Everolimus 3Thalidomide 2Sunitinib 2Streptozocin 2Octreotide 2Injections 2Fluorouracil 2surufatinib 1sargramostim 1recombinant interferon alpha 2b-like protein 1nimotuzumab 1motesanib diphosphate 1montanide ISA 51 1lutetium Lu 177 dotatate 1incomplete Freund's adjuvant 1ibrutinib 1ganitumab 1cabozantinib 1belzutifan 1batifiban 1atezolizumab 1abemaciclib 1Tegafur 1Specimen Handling 1PM 01183 1Metformin 1Melphalan 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adenoma, Islet Cell × ibrutinib × Clear all
NCT02575300 2020-09-11

Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
20 enrolled 11 charts
EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡